Gleevec is an inelastic crabmeat drug which created a monopoly in the pharmaceutic crabmeat drug market in the recent years. Since Gleevec is a life saving drug and it has no competition, it does not bunk affected by most of the economic conditions. Gleevecs closest contest is still in development phase and there is no guarantee that it will be completed or crystallise by the Federal Drug Administration (FDA) therefore Gleevec has no fear of a competitor coming into the pharmaceutical cancer drug market in the near future. Continuous studies are showing compromising affects of Gleevec on heart diseases besides leukemia and if sanction by the FDA in the future Gleevec can be commit to cure heart diseases which may expands Gleevecs use and pull its expense down due to increase of demand. Gleevec is a new instance of cancer drug; the first of its kind developed to indicate cancer by turning off an enzyme that types cells to become malignant and multiply. The U.S. Food and Drug Administration approved Gleevec (imatinib mesylate, or STI-571), in May 2001 for treating patients with three stages of chronic myelogenous leukemia (CML). Gleevec was approved under the U.S. governments deprive drug program, which provides financial incentives for the development of drugs to treat rare diseases.
grant was based on clinical studies that demonstrated the drugs effectiveness in 90% of the patients studied. CML is a personal credit line cancer in which there are too many improper snow-white ancestry cells. These cells, which dont work correctly, crowd out the prevalent white blood cells. Thi s clogs up the bloodstream and leaves the bo! dy with no defense against infections. The cause of CML is a gene on a chromosome called the Philadelphia chromosome. The gene makes a poisonous protein that causes cancer in white blood cells. Gleevec works... If you unavoidableness to get a full essay, order it on our website:
OrderCustomPaper.comIf you want to get a full essay, visit our page: write my paper
No comments:
Post a Comment